Panther Biotechnology Inc. (PBYA) 6.4000 $PBYA Panther

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Panther Biotechnology Inc. (PBYA) 6.4000 $PBYA

Panther Biotechnology Announces New Drug Candidate to Selectively Kill Leukemia Stem Cells
Marketwired - Fri Apr 17, 6:30AM CDT
Panther Biotechnology, Inc. (OTC PINK: PBYA), a biotechnology company specializing in the development of enhanced therapeutics for the treatment of neoplastic disorders, is pleased to announce today that it has entered into an exclusive global license agreement with the University of Rochester.

Panther Biotechnology Announces Agreement to Acquire Technology Assets of Faulk Pharmaceuticals
Marketwired - Tue Apr 07, 6:00AM CDT
Panther Biotechnology, Inc. (OTC PINK: PBYA), a biotechnology company specializing in the development of enhanced therapeutics for the treatment of neoplastic and autoimmune disorders, is pleased to announce today that it has entered into a definitive agreement with privately held Faulk Pharmaceuticals, Inc. to acquire Faulk's pharmaceutical technology assets. The transaction will provide Panther Biotechnology with a proprietary, multinationally patent protected, ligand-drug conjugate technology platform as well as a pipeline of drug product candidates that address unmet medical needs in oncology, autoimmune, antiviral and other disease indications.

Panther Biotechnology Announces Exclusive License Agreement With Northwestern University
Marketwired - Wed Apr 01, 9:02AM CDT
Panther Biotechnology, Inc. (OTC PINK: PBYA), a biotechnology company specializing in the development of enhanced therapeutics for the treatment of neoplastic and autoimmune disorders, is pleased to announce today that it has entered into an exclusive global license agreement with Northwestern University.

Panther Biotechnology Announces New Chief Executive Officer
Marketwired - Mon Mar 23, 9:52AM CDT
Panther Biotechnology, Inc. (OTC PINK: PBYA), a biotechnology company specializing in the development of enhanced therapeutics for the treatment of neoplastic and autoimmune disorders, is pleased to announce today that Evan Levine has accepted the position of Chief Executive Officer, as well as a seat on the Board of Directors.

Renowned USC/Norris Cancer Researcher, Dr. Heinz-Josef Lenz, Joins Panther Biotechnology Board of Directors
Marketwire - Thu Sep 11, 9:01AM CDT
Panther Biotechnology, Inc. (OTC Pink: PBYA) (PINKSHEETS: PBYA) announced today that Heinz-Josef Lenz, M.D., F.A.C.P., associate director of clinical research at USC/Norris Comprehensive Cancer Center and co-chair of the Southwest Oncology Group's Gastrointestinal Committee, has been appointed to Panther Biotechnology's Board of Directors.

Panther Biotechnology, Inc. Announces a 6-1 Forward Stock Split to Increase Liquidity of Their Common Stock and Intent to List on the NYSE or NASDAQ
Marketwire - Mon Sep 08, 10:59AM CDT
Panther Biotechnology, Inc. (OTC Pink: PBYA) (PINKSHEETS: PBYA) announced that a 6-1 forward stock split has been filed and has been approved by the Board of Directors of the Company and is subject to FINRA approval. The exact date of the split is still pending; however, the forward splitting of the common stock PBYA is being done to increase liquidity for current and future shareholders.

Panther Biotechnology, Inc. Announces the Appointment of Two Directors and Securing an Option on a Potential Blockbuster Novel Oncology Small Molecule With Northwestern University That Panther Will Fast Track Into the Clinic
Marketwire - Tue Aug 26, 9:15AM CDT
Panther Biotechnology, Inc. (OTCQB: PBYA) announced today the appointments of Mr. David Barshis and Mr. James Sapirstein to the company's Board of Directors. In addition the Panther announced it has secured an option agreement on a license for its lead technology, Numonafide a potential blockbuster novel small molecule compound in the liquid and solid tumor cancer market place, with Northwestern University.

Panther Biotechnology, Inc. Announces the Appointment of Two Directors and Securing an Option on a Potential Blockbuster Novel Oncology Small Molecule With Northwestern University That Panther Will Fast Track Into the Clinic
eTeligis - Tue Aug 26, 9:01AM CDT
CHICAGO, IL, United States, via ETELIGIS INC., 08/26/2014 - - Panther Biotechnology, Inc. (OTCQB: PBYA) announced today the appointments of Mr. David Barshis and Mr. James Sapirstein to the company's Board of Directors. In addition the Panther announced it has secured an option agreement on a license for its lead technology, Numonafide a potential blockbuster novel small molecule compound in the liquid and solid tumor cancer market place, with Northwestern University.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 718

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 182

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 314

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 262

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 258

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 105

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 216

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 110

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 385

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 0

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading

Top 5 Most Recently Viewed Articles

Omni-Lite Industries Reports Impressive Fiscal Q3 Results

Updated Category News Views 143

Highlights from Omni-Lite's Third Quarter Fiscal 2025 Outstanding Financial Performance Omni-Lite Industries Canada Inc. (TSXV: OML) recently reported its financial results for the third quarter of fiscal 2025, demonstrating notable growth and resilience. With revenue reaching approximately US$4.0 million, Omni-Lite saw a remarkable year-over-year increase of 7.0%...

Continue Reading
Assessing the Impact of UK Fiscal Policy on Housing Market Trends

Updated Category News Views 200

Understanding the Current UK Housing Market Dynamics The U.K. housing market is currently facing a notable slowdown, primarily driven by tax-related uncertainties associated with fiscal policies. As potential buyers adopt a more cautious stance, residential property transactions have seen a decline. This trend poses immediate risks for sectors linked to housing, including...

Continue Reading
Radford Racing School Unveils New Exciting Driving Adventures

Updated Category News Views 226

Exciting New Driving Experiences at Radford Racing School Recently, Radford Racing School, known as a leader in performance driving education, announced its latest offerings that promise to thrill automotive enthusiasts of all ages and skill levels. With the introduction of six new driving experiences, there's now something for everyone at their legendary racetrack....

Continue Reading
AppLovin CEO Sells $21.5 Million in Shares Amid Growth Momentum

Updated Category News Views 137

AppLovin CEO's Notable Stock Sale Recently, AppLovin Corp (NASDAQ: APP) made headlines with a significant financial event: CEO and Chairperson Arash Adam Foroughi sold over $21.5 million worth of company stock. According to the latest SEC filing, this noteworthy transaction occurred over just two days, with share prices varying from $98.08 to $112.33 during that time....

Continue Reading
Olverembatinib's Breakthrough Status Enhances Leukemia Treatment Options

Updated Category News Views 396

Olverembatinib Gains Breakthrough Therapy Designation Ascentage Pharma, a prominent global biopharmaceutical company, is making significant strides in the treatment of serious medical conditions. With its latest achievement, olverembatinib has secured a Breakthrough Therapy Designation in China for its use alongside low-intensity chemotherapy in newly-diagnosed patients...

Continue Reading